Peter Gilmour (PhD DABT) is a critical, hands-on consultant and expert in drug development who delivers.

He has a background in toxicology, pharmacology, biotechnology and immunology. His 25-year career spans academic drug discovery, US EPA environmental research and large pharma. Peter has worked as a project toxicologist and pharmacologist for numerous drug development projects from discovery to market authorization application, and has consulted for start-up, biotech and pharmaceutical companies for 8 years.

Peter has experience with all phases of drug discovery and development (candidate selection, designing and running IND enabling packages, biomarker selection, supporting product differentiation and preparing regulatory documentation) in small and large molecules and RNAi projects. A significant proportion of Peter’s projects have been industrial and academic collaborations, and he has an interest in drug repurposing and value estimation of potential drugs across numerous therapeutic areas, with a proven record of rejuvenating failing compounds to clinical assets.